Analysts Set Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Target Price at $14.30

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.30.

Several equities research analysts have recently commented on VNDA shares. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, June 4th. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $5.18 on Friday. The company has a current ratio of 2.16, a quick ratio of 2.15 and a debt-to-equity ratio of 0.01. The company has a market cap of $311.47 million, a price-to-earnings ratio of -1.28 and a beta of 0.60. The company’s 50 day moving average is $6.00 and its 200 day moving average is $6.93. Vanda Pharmaceuticals has a 12-month low of $4.14 and a 12-month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. The business had revenue of $51.72 million for the quarter, compared to analysts’ expectations of $54.98 million. On average, equities research analysts predict that Vanda Pharmaceuticals will post -2.2 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VNDA. AIGH Capital Management LLC purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth approximately $17,626,000. Millennium Management LLC lifted its holdings in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Vanda Pharmaceuticals by 552.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after purchasing an additional 599,818 shares in the last quarter. Marshall Wace LLP lifted its holdings in Vanda Pharmaceuticals by 945.9% during the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after purchasing an additional 426,620 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Vanda Pharmaceuticals by 11.2% in the first quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after purchasing an additional 378,598 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.